HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carrington, A. L. Articles by Boulton, A. J.M. Search for Related Content PubMed PubMed Citation Articles by Carrington, A. L. Articles by Boulton, A. J.M. Social Bookmarking                What's this?

Can Motor Nerve Conduction Velocity Predict Foot Problems in Diabetic Subjects Over a 6-Year Outcome Period?

From the Department of Medicine, Manchester Royal Infirmary, Manchester, U.K

OBJECTIVE—This study examined motor nerve conduction velocity (MNCV) and other peripheral nerve and vascular tests as predictors for foot ulceration, amputation, and mortality in diabetes over a 6-year follow-up period.

RESEARCH DESIGN AND METHODS—We recruited 169 diabetic subjects (without significant peripheral vascular disease with an ankle brachial pressure index [ABPI] 0.75) for the study and separated them into groups (to ensure diversity of nerve function). The control group consisted of 22 nondiabetic people. At baseline, all subjects underwent assessment of MNCV; vibration, pressure, and temperature perception thresholds; peripheral vascular function; and other diabetes assessments.

RESULTS—Over the 6-year outcome period, 37.3% of the diabetic subjects developed at least one new ulcer, 11.2% had a lower-limb amputation (LLA) (minor or major), and 18.3% died. Using multivariate Cox’s regression analysis (RR [95% CI] and removing previous ulcers as a confounding variable, MNCV was found to be the best predictor of new ulceration (0.90 [0.84–0.96], P = 0.001) and the best predictors of amputation were pressure perception threshold (PPT) (5.18 [1.96–13.68], P = 0.001) and medial arterial calcification (2.88 [1.13–7.35], P = 0.027). Creatinine (1.01 [1.00–1.01], P < 0.001), MNCV (0.84 [0.73–0.97], P = 0.016), and skin oxygen levels (14.32 [3.04–67.52], P = 0.001) were the best predictors of mortality.

CONCLUSIONS—This study shows that MNCV, which is often assessed in clinical trials of neuropathy, can predict foot ulceration and death in diabetes. In addition, tests of PPT and medial arterial calcification can be used in the clinic to predict LLA in diabetic subjects.

Abbreviations: ABPI, ankle brachial pressure index • CV, coefficient of variation • LLA, lower-limb amputation • MNCV, motor nerve conduction velocity • PN, peripheral neuropathy • PPT, pressure perception threshold • PVD, peripheral vascular disease • TcpO₂, transcutaneous partial pressure of oxygen • TcpCO₂, transcutaneous partial pressure of carbon dioxide • TPT, temperature perception threshold • VPT, vibration perception threshold

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				U. Del Carro, P. Fiorina, S. Amadio, L. De Toni Franceschini, A. Petrelli, S. Menini, F. M. Boneschi, S. Ferrari, G. Pugliese, P. Maffi, et al. Evaluation of Polyneuropathy Markers in Type 1 Diabetic Kidney Transplant Patients and Effects of Islet Transplantation: Neurophysiological and skin biopsy longitudinal analysis Diabetes Care, December 1, 2007; 30(12): 3063 - 3069. [Abstract] [Full Text] [PDF]

				A. J.M. Boulton Whither Clinical Research in Diabetic Sensorimotor Peripheral Neuropathy?: Problems of end point selection for clinical trials Diabetes Care, October 1, 2007; 30(10): 2752 - 2753. [Full Text] [PDF]

				A. Silvestro, N. Diehm, H. Savolainen, D.-D. Do, J. Vogele, F. Mahler, S. Zwicky, and I. Baumgartner Falsely high ankle-brachial index predicts major amputation in critical limb ischemia Vascular Medicine, May 1, 2006; 11(2): 69 - 74. [Abstract] [PDF]

				H. M. Rathur and A. J. M. Boulton Recent advances in the diagnosis and management of diabetic neuropathy J Bone Joint Surg Br, December 1, 2005; 87-B(12): 1605 - 1610. [Full Text] [PDF]

				D. Ziegler, E. Siekierka-Kleiser, B. Meyer, and M. Schweers Validation of a Novel Screening Device (NeuroQuick) for Quantitative Assessment of Small Nerve Fiber Dysfunction as an Early Feature of Diabetic Polyneuropathy Diabetes Care, May 1, 2005; 28(5): 1169 - 1174. [Abstract] [Full Text] [PDF]

				N. Tentolouris, S. Al-Sabbagh, M. G. Walker, A. J.M. Boulton, and E. B. Jude Mortality in Diabetic and Nondiabetic Patients After Amputations Performed From 1990 to 1995: A 5-year follow-up study Diabetes Care, July 1, 2004; 27(7): 1598 - 1604. [Abstract] [Full Text] [PDF]

				A. J.M. Boulton, R. A. Malik, J. C. Arezzo, and J. M. Sosenko Diabetic Somatic Neuropathies Diabetes Care, June 1, 2004; 27(6): 1458 - 1486. [Full Text] [PDF]

				Z. T. Bloomgarden Diabetes Complications Diabetes Care, June 1, 2004; 27(6): 1506 - 1514. [Full Text] [PDF]

				M. J. Brown, S. J. Bird, S. Watling, H. Kaleta, L. Hayes, S. Eckert, and H. L. Foyt Natural Progression of Diabetic Peripheral Neuropathy in the Zenarestat Study Population Diabetes Care, May 1, 2004; 27(5): 1153 - 1159. [Abstract] [Full Text] [PDF]